AIDS - Related Kaposi's Sarcoma - Pipeline Review, H2 2015

Date: July 22, 2015
Pages: 57
Price:
US$ 2,000.00 US$ 1,600.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A43459B5DB8EN
Leaflet:

Download PDF Leaflet

AIDS - Related Kaposi's Sarcoma - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘AIDS - Related Kaposi's Sarcoma - Pipeline Review, H2 2015’, provides an overview of the AIDS - Related Kaposi's Sarcoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for AIDS - Related Kaposi's Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for AIDS - Related Kaposi's Sarcoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of AIDS - Related Kaposi's Sarcoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for AIDS - Related Kaposi's Sarcoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the AIDS - Related Kaposi's Sarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the AIDS - Related Kaposi's Sarcoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for AIDS - Related Kaposi's Sarcoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding AIDS - Related Kaposi's Sarcoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
AIDS - Related Kaposi's Sarcoma Overview
Therapeutics Development
Pipeline Products for AIDS - Related Kaposi's Sarcoma - Overview
Pipeline Products for AIDS - Related Kaposi's Sarcoma - Comparative Analysis
AIDS - Related Kaposi's Sarcoma - Therapeutics under Development by Companies
AIDS - Related Kaposi's Sarcoma - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Unknown Stage Products
AIDS - Related Kaposi's Sarcoma - Products under Development by Companies
AIDS - Related Kaposi's Sarcoma - Companies Involved in Therapeutics Development
Aphios Corporation
AstraZeneca Plc
Biogenomics Limited
CytRx Corporation
AIDS - Related Kaposi's Sarcoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
aldoxorubicin hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CS-TATI-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
interferon alfa-2a (recombinant) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
interferon alfa-2b (recombinant) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
paclitaxel nanosomal - Drug Profile
Product Description
Mechanism of Action
R&D Progress
selumetinib sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AIDS - Related Kaposi's Sarcoma - Recent Pipeline Updates
AIDS - Related Kaposi's Sarcoma - Dormant Projects
AIDS - Related Kaposi's Sarcoma - Dormant Projects
AIDS - Related Kaposi's Sarcoma - Discontinued Products
AIDS - Related Kaposi's Sarcoma - Product Development Milestones
Featured News & Press Releases
Jan 08, 2015: CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results as a Treatment for HIV-Related Kaposi's Sarcoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for AIDS - Related Kaposi's Sarcoma, H2 2015
Number of Products under Development for AIDS - Related Kaposi's Sarcoma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
AIDS - Related Kaposi's Sarcoma - Pipeline by Aphios Corporation, H2 2015
AIDS - Related Kaposi's Sarcoma - Pipeline by AstraZeneca Plc, H2 2015
AIDS - Related Kaposi's Sarcoma - Pipeline by Biogenomics Limited, H2 2015
AIDS - Related Kaposi's Sarcoma - Pipeline by CytRx Corporation, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
AIDS - Related Kaposi's Sarcoma Therapeutics - Recent Pipeline Updates, H2 2015
AIDS - Related Kaposi's Sarcoma - Dormant Projects, H2 2015
AIDS - Related Kaposi's Sarcoma - Discontinued Products, H2 2015

LIST OF FIGURES

Number of Products under Development for AIDS - Related Kaposi's Sarcoma, H2 2015
Number of Products under Development for AIDS - Related Kaposi's Sarcoma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

Aphios Corporation
AstraZeneca Plc
Biogenomics Limited
CytRx Corporation
Skip to top


Ask Your Question

AIDS - Related Kaposi's Sarcoma - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: